Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,300 peer-reviewed publications.

The CPRD bibliography is updated on a monthly basis (last updated 4 December 2019) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

(PDF, 3MB, 193 pages)

 

Export 10 results:
Author Title Type [ Year(Asc)]
Filters: Author is Douros, A.  [Clear All Filters]
2018
D. Abrahami, Douros, A., Yin, H., Yu, O. H. Y., Renoux, C., Bitton, A., and Azoulay, L., Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study, Bmj, vol. 360, p. k872, 2018.
A. Douros, Filion, K. B., Yin, H., Yu, O. H., Etminan, M., Udell, J. A., and Azoulay, L., Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Incident Diabetic Retinopathy, Diabetes Care, vol. 41, pp. 2330-2338, 2018.
D. Abrahami, Douros, A., Yin, H., Yu, O. H., Faillie, J. L., Montastruc, F., Platt, R. W., Bouganim, N., and Azoulay, L., Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study, Bmj, vol. 363, p. k4880, 2018.
A. Douros, Dell'Aniello, S., Yu, O. H. Y., Filion, K. B., Azoulay, L., and Suissa, S., Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study, Bmj, vol. 362, p. k2693, 2018.
A. Douros, Abrahami, D., Yin, H., Yu, O. H. Y., Renoux, C., Hudson, M., and Azoulay, L., Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes, Epidemiology, vol. 29, pp. 904-912, 2018.
[Page last reviewed 6 December 2019]